From the U.315 INSERM, F 13009 Marseille, France, the
Laboratoire d'Immunologie, INSERM U. 387, F13009 Marseille,
France, and the ** URA CNRS 1924, Laboratoire de Biologie Cellulaire,
Université Aix-Marseille II, Faculté de Pharmacie,
13385 Marseille, France
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have previously described an inverse relationship between Cdx1 and Cdx2 mRNA levels and the extent of dysplasia and severity of clinical outcome in colorectal carcinoma, suggesting that altered expression of these genes was associated with colorectal carcinogenesis or tumor progression. To investigate further their involvement in the physiopathology of colorectal cancer, HT29 colon carcinoma cells that show very low Cdx expression were transfected with Cdx1 and/or Cdx2 cDNA to elicit their overexpression. Growth rate, tumorigenicity, resistance to apoptosis, and migration potential of the corresponding cells were analyzed. Growth rate of cells overexpressing Cdx2 decreased by half, whereas overexpression of Cdx1 had no effect. However, cells overexpressing both Cdxs had a growth rate reduced to 20% of control. In cells overexpressing Cdx1 or Cdx2, tumorigenicity and resistance to apoptosis induced by serum starvation, ceramide, or staurosporine were not changed compared with control cells; yet phorbol ester-stimulated cell migration was decreased by 50%. In cells overexpressing both Cdx1 and Cdx2, tumorigenicity was decreased by 50%, resistance to apoptosis was significantly lowered, and stimulated cell migration was further decreased to 15% of control compared with cells expressing Cdx1 or Cdx2. Finally, cells overexpressing both Cdxs showed strongly decreased Bcl-2 expression, which could account for their increased sensitivity to apoptosis. These findings show that, in HT29 cells, both Cdx1 and Cdx2 genes must be expressed to reduce tumorigenic potential, to increase sensitivity to apoptosis, and to reduce cell migration, suggesting that the two genes control the normal phenotype by independent pathways. This may explain why loss of Cdx1 or Cdx2 expression is associated with tumor development and invasiveness in colorectal tumors.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In an effort to characterize the mechanisms involved in colorectal
cancer initiation and progression, we have developed a strategy based
on the constitution of a large repertoire of transcripts from a
colorectal tumor, all characterized by partial sequencing (1).
Expression of these expressed sequence tags in normal and cancerous
colon was compared, and those most differentially expressed were
selected. Genes detected by these means may be causative or
instrumental in tumor induction or/and progression. Looking for such
genes, we found that the Cdx1 and Cdx2 homeotic genes were concomitantly down-regulated in about 85% of colorectal cancers (2). Such low expression of Cdx1 or Cdx2
in colon carcinoma was verified by immunohistochemistry (3, 4) and by
reverse transcription polymerase chain reaction (5) studies.
Cdx1 and Cdx2 are interesting candidates that
could play a role in colon cancer pathology because Chawengsaksophak
et al. (6) recently reported the occurrence of multiple
intestinal adenomatous polyps in the proximal colon of
Cdx2+/ mice, suggesting that lowering
Cdx2 levels in intestinal cells would suffice to induce
intestinal tumors. Also, Suh and Traber showed that expression of the
Cdx2 in an intestinal cell line could stimulate cell
differentiation and growth arrest (7). A corrolary of these findings
might be that the down-regulation of Cdx2 would account for
the loss of differentiation and exaggerated cellular growth observed in
intestinal tumors.
In the present paper we have used HT29, a cell line derived from a colon tumor that shows very low Cdx1 and Cdx2 expression, to investigate the role of these homeotic genes in the physiopathology of colorectal cancer. To this end, HT29 cells were transfected with Cdx1 and Cdx2 expression plasmids, alone or in combination. The impact of Cdx overexpression on important events involved in tumor progression and invasion such as tumorigenicity, resistance to apoptosis, and cell migration was analyzed. It was found that Cdx1 and Cdx2 cooperate to reduce the malignancy of HT29 cells.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell Culture-- The human colon carcinoma cell line HT29 was obtained from Dr. A. Zweibaum (INSERM U.178). Cells were routinely cultivated at 37 °C in a 5% CO2, 95% air atmosphere in Dulbecco's modified Eagle's medium containing 10% (v/v) fetal calf serum (Life Technologies, Inc.), 4 mM L-glutamine, 50 units/ml of penicillin, and 50 µg/ml streptomycin. Upon reaching 80-90% confluency, cells were dissociated with 0.05% trypsin and 0.02% EDTA in Puck's saline A and replated into 100-mm Petri dishes.
Establishment of Stable Cell Lines-- All cDNA inserts were generated by reverse transcription polymerase chain reaction using RNA from human small intestine as template, and primers were selected from the cDNA sequence of Cdx1 and Cdx2 (2). To synthesize the Cdx1 cDNA insert, the forward primer was 5'-GGGAATTCAGGTGAGCAGTCGCTGGTCGTC-3' and the reverse primer was 5'-GGGAATTCACAGGAGCCACACTCCCAGCACC-3', which yielded a 942-base pair product (nucleotides 1-942 of human Cdx1). To synthesize the Cdx2 cDNA insert, the forward primer was 5'-GGGAATTCAGGCAGCATGGTGAGGTCTG-3' and the reverse primer was 5'-GGGAATTCCTGAGGAGTCTAGCAGAGTCC-3', which yielded a 1048-base pair product (nucleotides 32-1080 of human Cdx2). The coding sequences of Cdx1 and Cdx2 were amplified with oligonucleotides that incorporated EcoRI restriction sites (underlined). The Cdx1 and Cdx2 polymerase chain reaction products were EcoRI-digested and subcloned into the EcoRI restriction site of the mammalian expression vector pcDNA3 (Invitrogen), downstream from the cytomegalovirus promoter. That plasmid also contained the aminoglucoside phosphotransferase 3' gene that confers resistance to the antibiotic geneticin (G418 sulfate). Using this approach we obtained expression vectors for Cdx1 (pcDNA3Cdx1S) and Cdx2 (pcDNA3Cdx2S). Sequences were verified by the chain termination method using the T7 Sequencing kit (Amersham Pharmacia Biotech). As control, we have used the pcDNA3CAT plasmid in which the chloramphenicol acetyltransferase gene was also under the control of the cytomegalovirus promoter. We also constructed the pCEP4Cdx2S vector. The Cdx2 DNA insert was recovered from the pcDNA3Cdx2S plasmid by endonuclease restriction and directionally subcloned into the pCEP4 vector (Invitrogen), in which Cdx2 expression is under the control of the cytomegalovirus promoter but confers resistance to hygromycin. This construction was checked by restriction pattern. Plasmid DNA was purified with the Qiagen plasmid kit (Diagen, Hilden, Germany), and DNA concentration was measured by spectrophotometry.
The pcDNA3Cdx1S, pcDNA3Cdx2S, and pcDNA3CAT plasmids were stably transfected into HT29 cells using the Lipofectin reagent (8) as described by the supplier (Life Technologies, Inc.). To select for stable transfectants, the cells were cultivated over 3-4 weeks in media containing G418 (600 µg/ml) starting 48 h after transfection. Surviving colonies were pooled and maintained in standard culture medium supplemented with G418 (400 µg/ml). To obtain cells expressing both Cdx1 and Cdx2, the HT29 pcDNA3Cdx1S-transfected cells were transfected with the pCEP4Cdx2S plasmid and selected with G418 (400 µg/ml) and hygromycin (300 µg/ml) concomitantly. Surviving clones were pooled and maintained in standard culture medium supplemented with G418 (400 µg/ml) and hygromycin (300 µg/ml).HT/Cdx1S, HT/Cdx2S, HT/Cdx1S2S, and HT/CAT Cells--
To avoid
clonal variations, after transfection and selection with antibiotics,
more than 100 independent colonies of each transfection were pooled,
replated, grown to confluence, dissociated, aliquoted, and stored at
140 °C. After replating, cells were used for less than six
passages. Transfected cells were grown with appropriate selection
antibiotic, except during experiments. We used Northern blot assay to
test whether HT29 cells expressed the transfected genes. RNA was
purified from HT29-transfected cells, and 20 µg of each RNA was
subjected to electrophoresis on 1% agarose containing 2.2 M formaldehyde and transferred to nylon membranes (Nytran
Plus) as described (9). For RNA probes, the membranes were
prehybridized at 65 °C for 4 h in 5× SSC, 50 mM
Hepes (pH 6.8), 1% SDS, 5× Denhardt, 2 mM EDTA, 50%
formamide, and sonicated salmon sperm DNA (200 µg/ml). Hybridization
was performed at 65 °C during 16-20 h in the above solution
containing [32P]UTP cRNA probe (1 × 106
cpm/ml). The Cdx1 and Cdx2 cRNA probes were
respectively transcribed from the linearized 6G2 and 32D6 plasmids (2)
using Promega Transcription Riboprobe System (Promega). After
hybridization, filters were washed with 0.1× SSC, 0.1% SDS twice, 30 min at 75 °C. A 28 S ribosomal [32P]dCTP-labeled
cDNA probe was used as a control to evaluate RNA loading and
transfer. Specific hybridization of probes was analyzed by exposure to
a Kodak X-Omat AR film.
Analysis of the Cdx1 and Cdx2 Proteins--
Expression of
Cdx1 was estimated by monitoring the activity of the
Cdx1-inducible Hoxa-7 promoter in HT/Cdx1S and HT/Cdx1S2S cells. These cells express Cdx1 (see above). The Hoxa-7 LacZ
(AX470 construct) and TK LacZ (control) plasmids (kindly provided by Dr. P. Gruss, Max Planck Institute for Biophysical Chemistry, Göttingen) have been previously described (10). The cells were transfected using the Lipofectin reagent as described above. At 48 h post-transfection cell extracts were prepared, and -galactosidase assay was performed essentially as described previously (9).
Cell Proliferation-- HT/Cdx1S, HT/Cdx2S, HT/Cdx1S2S, and HT/CAT cells were plated in 12-well tissue culture plates at 5 × 103 cells/well. After 1, 2, 3, 4, 5, and 6 days, cell number was estimated by MTT1 assay (Sigma) and/or counted on a hemacytometer. Two sets of experiments were done, each one in triplicate.
Tumorigenicity Assays-- Tumorigenicity was assayed by subcutaneous injection of 5 × 106 HT/Cdx1S, HT/Cdx2S, HT/Cdx1S2S, HT/CAT, or HT29 parental cells resuspended in 200 µl of phosphate-buffered saline into the flanks of 4-week-old nude mice. They were maintained under specific pathogen-free conditions and fed with sterile commercial chow (U.A.R., Villemoisson-Sur-Orge, France) and water ad libitum. Tumors were measured in two dimensions with linear calipers at the indicated days.
Serum Starvation-, Ceramide- and Staurosporine-induced Apoptosis-- To assess differences in resistance to apoptosis, the HT29-transfected cells were submitted to three apoptotic stimuli, i.e. serum starvation, ceramide, and staurosporine. For serum starvation-induced apoptosis, 5 × 105 cells were plated on 50-mm Petri dishes, and after 48 h, the cells were serum starved for 4 days. Surviving cells were quantified by MTT following the instructions of the supplier (Sigma), and DNA fragmentation was measured by gel electrophoresis and by flow cytometry. Gel electrophoresis was performed using standard protocols (9) and flow cytometry as follows. Cells were harvested from culture and permeabilized in 500 µl of 50 µg/ml propidium iodide, 0.05% Nonidet P-40, 4000 units/ml RNase in phosphate-buffered saline. Reagents were obtained as a kit from Coultronics France (Margency, France) and used according to the manufacturer's recommendations. After vortexing, samples were allowed to equilibrate at room temperature in the dark for at least 1 h before analysis. Propidium iodide fluorescence analysis was performed in a flow cytometer (EPICS, Coulter Corporation).
Drug-induced apoptosis was elicited by treating cells with 20 µM ceramide (Euromedex) or 100 nM staurosporine (Sigma) for the indicated times. In preliminary studies, apoptosis induced by ceramide and staurosporine was confirmed by analysis of DNA fragmentation on gel electrophoresis and flow cytometry. The number of surviving cells was estimated by MTT assay. Data shown are the mean ± S.E. of three independent experiments performed in duplicate, and the percentage of surviving cells was defined as the number of ceramide- or staurosporine-treated cells relative to untreated cells.Bcl-2 Expression in HT/Cdx1S, HT/Cdx2S, HT/Cdx1S2S, and HT/CAT Cells-- Expression of Bcl-2 was analyzed by Western blotting. Cells were lysed in ice-cold lysis buffer containing 150 mM NaCl, 1% Triton X-100, 10 mM Tris (pH 7.4), 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, and 5 mM benzamidine for 20 min at 4 °C. Protein concentration was measured by the Bradford method (12), and 100-µg samples were mixed with 2× Laemmli buffer. Western blot analysis was performed according to standard procedures (9). Briefly, samples were resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose filters (Schleicher & Schuell), and incubated with the primary antibody diluted 1:2500 in NaCl/Pi (pH 7.4) containing 3% nonfat dry milk for 2 h at room temperature under gentle shaking. The primary anti-human Bcl-2 antibody was a monoclonal antibody purchased from Boehringer Mannheim (Meylan, France; reference number 1 624 989). After incubation, the filters were washed and incubated for 1 h at room temperature with horseradish peroxidase-linked F(ab)2 fragment anti-mouse secondary antibody (1:4000, Amersham Pharmacia Biotech). The filters were washed again and developed using enhanced chemiluminiscence imaging system (Amersham Pharmacia Biotech).
Cell Migration Assays-- Migration of HT/Cdx1S, HT/Cdx2S, HT/Cdx1S2S, HT/CAT, or HT29 parental cells was studied by a modification of the wound closure assay described by Bürk (14). Briefly, cells were plated in 35-mm culture wells and grown to 95% confluence. Then the monolayer was denuded of cells using a sterile razor blade to make a wound showing a sharp boundary. The cells were then washed with serum-free medium and returned to the incubator in serum-free medium containing 100 nM phorbol 12-myristate 13-acetate (PMA) (Sigma). In order to distinguish between the contributions of migration and proliferation to the wound closure process, migration assays were also carried out in the presence of mitomycin C (5 µg/ml). After wounding, cells were incubated for 24 h. After fixation with 2.5% formaldehyde in phosphate-buffered saline, the number of cells having crossed the wound margin was counted in eight different areas chosen randomly. Experiments were carried out in triplicate. Data presented under results are expressed as the means ± S.E. of two independent sets of experiments.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Establishment of Stable Cdx Transfectants-- The transfection efficiency was evaluated by measuring chloramphenicol acetyltransferase activity in cell extracts for cells transfected with the chloramphenicol acetyltransferase gene (data not shown) and Cdx mRNA levels by Northern blot analysis for cells transfected with the Cdx1 and Cdx2 expression plasmids. Results shown in Fig. 1 indicate that Cdx1 and Cdx2 genes were expressed at very low levels in HT29 parental and HT/CAT-transfected cells because the corresponding signals were barely detectable after a 10 days exposure of the blots. By contrast, the transfected cell line expressed high levels of the corresponding transcript or of both transcripts in the case of Cdx1 and Cdx2 double transfectants.
|
Proliferation of HT/Cdx1S, HT/Cdx2S, HT/Cdx1S2S, and HT/CAT Cells-- The rate of growth of each transfected cell line is shown on Fig. 2. Direct counting of the cells and indirect estimation of cell number by MTT assay led to similar results. Growth of HT/CAT cells was taken as reference because these cells have been transfected and selected under the same conditions as the Cdxs-transfected cells while expressing a nonrelevant protein. In fact, HT/CAT cells and the parental HT29 cells grew very similarly, suggesting little influence of transfection and selection, if any, on cell proliferation (data not shown). The doubling time of HT29 cells was about 24 h under our experimental conditions (Fig. 2). Growth of HT/Cdx1S cells, which overexpress Cdx1, was similar to that of control cells. By contrast, growth of HT/Cdx2S cells, which overexpress Cdx2, was slower. Surprisingly, HT/Cdx1S2S cells, which overexpress concomitantly Cdx1 and Cdx2, grew significantly slower than cells overexpressing Cdx2 alone (Fig. 2). These results confirmed a previous report (7) that Cdx2 expression inhibited the growth of intestine-derived cells. In addition, they demonstrated that Cdx1, although not a growth inhibitor by itself, could enhance the inhibitory activity of Cdx2.
|
Cdx1 and Cdx2 Cooperate to Inhibit Tumorigenicity-- The tumorigenic potential was assessed by measuring the size of the tumors that develop after subcutaneous injection of a same number of the transfected cells into athymic nude (nu/nu) mice. Tumor formation occurred with all cell lines. The growth of the tumors obtained after grafting with HT29 parental, HT/CAT control cells, and Cdx1 or Cdx2 transfected cells was not significantly different. By contrast, a 50% reduction in tumor growth rate was observed when HT29 cells expressed concomitantly the Cdx1 and Cdx2 homeotic genes (Fig. 3).
|
Increased Sensitivity to Serum Starvation-, Ceramide- and Staurosporine-induced Apoptosis of HT/Cdx1S2S Cells-- Because tumor growth and progression could be associated with a resistance to apoptosis of the transformed cells, we looked into whether overexpression of Cdx1 or/and Cdx2 would change the sensitivity of HT29 cells to apoptosis. Apoptosis was quantified by measuring DNA fragmentation by flow cytometry and gel or by evaluating cell survival by MTT assay. When HT/Cdx1S, HT/Cdx2S, HT/Cdx1S2S, HT/CAT control, or HT29 parental cells were grown in the presence of serum, subdiploidy was observed in less than 1% of cells (data not shown), indicating that Cdx expression did not interfere with spontaneous apoptosis. When cells were starved from serum for 4 days, the percentage of apoptotic cells increased to 5-7% in HT/Cdx1S, HT/Cdx2S, HT/CAT, and HT29 cells. It was significantly higher (16%) in HT/Cdx1S2S cells (Fig. 4). Confirmation of these data was sought by measuring the apoptosis rate induced by ceramide and staurosporine, which are known to stimulate apoptosis. The optimal drug concentration that triggered apoptosis in HT29 parental cells was determined by DNA fragmentation and cell survival assays (data not shown). Then the survival of HT/Cdx1S, HT/Cdx2S, HT/Cdx1S2S, HT/CAT control, or HT29 parental cells treated by these amounts of staurosporine and ceramide was measured over a period of 18 h. Under these conditions, cells cotransfected with Cdx1 and Cdx2 but not the cells overexpressing either Cdx1 or Cdx2 showed increased apoptosis rate, compared with parental or control HT29 cells (Fig. 4). These results confirm that sensitivity to stimulated apoptosis was increased only when Cdx1 and Cdx2 were concomitantly overexpressed.
|
Bcl-2 Is Down-regulated in HT/Cdx1S2S Cells-- We investigated whether sensitivity to stimulants of apoptosis was associated with modulation of Bcl-2 expression. Bcl-2 expression was monitored by Western blot analysis of HT29-transfected cells, using a specific monoclonal antibody. In cells expressing either Cdx1 or Cdx2, no change could be evidenced (Fig. 5). However, in cells in which Cdx1 and Cdx2 were concomitantly expressed, the Bcl-2 signal was significantly decreased.
|
Cdx1 or Cdx2 Overexpression Inhibits Phorbol Ester-stimulated Cell Migration-- Cancer aggressivity depends mostly on tumor invasiveness, and cell migration is a determining step in this process. This is why we studied the modulations of cell migration consecutive to Cdx1 or/and Cdx2 overexpression. Cell migration was measured by counting the number of cells having crossed the margin of a wound made in a monolayer at a given time after wounding (14). HT29 cell migration was spontaneously very slow, but it was stimulated very significantly after cell treatment by PMA. As shown in Fig. 6, HT29 and HT/CAT migrated at a similar rate after stimulation by PMA. Under these conditions, the migration of HT/Cdx1S and HT/Cdx2S cells was profoundly impaired because it was only 40 and 37% of HT/CAT cells, respectively. Interestingly, the migration of HT/Cdx1S2S was only 16% that of HT/CAT cells, indicating that overexpression of both Cdx1 and Cdx2 resulted in a more profound inhibition of PMA-stimulated cell migration than overexpression of Cdx1 or Cdx2. Quite similar results were obtained upon treatment with mitomycin C (5 µg/ml), which inhibits cell proliferation, indicating that it was indeed cell migration that contributed dominantly to the wound closure process.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Several authors have proposed that altered expression of homeotic genes could be associated with cell transformation and cancer progression (16, 17) and that hypothesis was raised for various cancers (18, 19) including colon carcinoma (20). Previously, we (2) and others (3-5) have reported a decreased expression of Cdx1 and/or Cdx2 in the tumors of several patients, compared with the adjacent normal colon. Furthermore, an inverse correlation was found between the severity of dysplasia and expression of Cdx1 and Cdx2. In order to get further insight into the role of these homeotic genes in colon carcinogenesis, particularly in tumor progression, we choose to analyze the consequences of re-establishing their expression in HT29 cells. These cells derive from a colon carcinoma, and they express extremely low levels of Cdx1 and Cdx2 mRNA (Fig. 1). By appropriate transfections we obtained HT29-derived cell lines overexpressing Cdx1, Cdx2, or both and compared their capacity for tumor formation, their sensitivity to apoptosis, and their ability for migration.
The first parameter expected to be altered by Cdx expression
was cell growth. Because Cdx mRNA expression is
down-regulated in colon carcinoma (2-5), we looked into whether
inducing Cdx overexpression would decrease the growth rate
of HT29 cells. With respect to parental cells, the growth rate of
HT/Cdx2S cells was indeed decreased by 50%, whereas that of HT/Cdx1S
cells was not affected. This is consistent with previous reports
showing a decreased growth rate in nontumoral intestine-derived cells
overexpressing the Cdx2 (7) and a normal growth rate in
epithelial intestinal cells of Cdx1/
mice
(15). In addition, we observed that overexpression of Cdx1
strongly potentiated the effect of Cdx2 overexpression, the growth rate of HT/Cdx1S2S being only 20% of control. Thus,
Cdx2 seems to be directly involved in the control of cell
growth, whereas Cdx1 would only enhance Cdx2
action.
Then we studied the relationship between Cdx expression and
tumorigenicity. All cell lines, including controls, induced tumors when
injected into nude mice. Cells overexpressing chloramphenicol acetyltransferase, Cdx1, or Cdx2 generated tumors
that grew at the same rate as parental cells. However, the growth rate
of tumors generated by cells overexpressing Cdx1 and
Cdx2 was decreased by half. These results demonstrate that
concomitant expression of Cdx1 and Cdx2 is
required to reduce the tumorigenicity of HT29 cells but not sufficient
to prevent tumor formation; conversely, they indicate that decreased
expression of one of the two Cdxs may result in increased
tumorigenicity. However, analyzing our findings in view of results
obtained in vivo revealed some discrepancies. In
Cdx1/
mice, the growth rate of epithelial
intestinal cells was unchanged, and the animals did not develop
intestinal tumors (15). Cdx2
/
mice could not
be analyzed because they died early after conception but 90% of
Cdx2+/
mice developed intestinal tumors within
the first three months of life (6). Hence, adequate expression of
Cdx2 is also mandatory in vivo to prevent
uncontrolled cell growth, but contrary to what was obtained in
vitro with HT29, concomitant preservation of Cdx1 expression is apparently not essential. Partial complementation by
another Cdx in Cdx1
/
mice might
account for that discrepancy. Nevertheless, these findings support the
hypothesis that situations leading to decreased Cdx
expression in colon cells would likely be associated with increased
tumorigenicity.
The third aspect that we investigated was whether Cdx expression altered cell response to apoptotic agents, because decreased susceptibility of most tumoral cells to apoptosis favors tumor growth and increases cell resistance to cytotoxic agents (21). In normal culture conditions, the apoptosis rate was less than 1% in HT/CAT control or HT29 parental cells and did not change upon overexpression of Cdx1 and/or Cdx2, suggesting that Cdx overexpression did not induce apoptosis. When cells were exposed to serum starvation, ceramide, or staurosporine, apoptosis was induced to the same extent in control cells and cells overexpressing Cdx1 or Cdx2. By contrast, cells expressing both Cdx genes showed markedly increased sensitivity to induced apoptosis (Fig. 4). Thus, as reported above for tumorigenicity, underexpression of either Cdx1 or Cdx2 would confer a more severe phenotype to colon cells by increasing their resistance to apoptosis.
We found evidence that sensitivity to stimulated apoptosis was accompanied by down-regulation of the Bcl-2 protein in HT/Cdx1S2S cells (Fig. 5). Overexpression of Bcl-2 protein, obtained by transfection of the Bcl-2 gene into human colonic cells, renders these cells resistant to butyrate-induced apoptosis (22). These findings suggest that the anti-apoptotic gene Bcl-2 is involved in the pathway by which the Cdx control apoptosis in colon cells.
The ability of cells to migrate is the last parameter that we analyzed in conjunction with Cdx expression. This is an important aspect because cell migration is required for invasivity and metastasis (23). Migration is a complex function that depends on a dynamic regulation of the interaction of cell surface adhesion receptors with their ligands on the ouside of the cell and with the cytoskeleton on the inside, the whole process being controlled by growth factors. In this study, it was found that overexpression of either Cdx1 or Cdx2 was sufficient to reduce the PMA-stimulated migration by 60%. Yet, here again, co-operation of Cdx1 and Cdx2 led to a much stronger effect, cell migration being inhibited by 85%. It is therefore very likely that loss of Cdx1 or Cdx2 expression from normal colon cells would significantly increase their migration potential.
It was concluded from these studies that concomitantly increasing the expression of Cdx1 and Cdx2 conferred to HT29 colon cancer cells a much less aggressive phenotype. Their rate of growth and tumorigenicity were decreased, their sensitivity to apoptosis was increased, and their migration upon stimulation by PMA was strongly reduced. Overexpressing only one of the Cdxs produced a weaker effect or was ineffective. Hence, reduced expression of one of the two Cdxs would suffice to maintain an aggressive phenotype, in agreement with previous findings that decreased expression of Cdx1 or Cdx2 was associated with colon cancer (2). These results suggest that restoration of Cdx expression in colon cancer cells would be a promising therapeutic strategy, provided that Cdx1 and Cdx2 are concomitantly induced.
The present findings could also be analyzed in terms of carcinogenesis because, if increasing the expression of the Cdxs in colon cancer cells decreases the aggressivity of their phenotype, one can assume that in normal colon cells any event leading to decreased expression of Cdx1 or Cdx2 would participate in carcinogenesis. Hence, the two homeotic genes must independently control pathways that are involved in maintaining the normal phenotype. The mechanisms by which Cdx gene products influence the phenotype of the cells are presently unknown, but they could be part of the control of cell cycle and differentiation as reported for the retinoblastoma gene (RB1), because overexpression of that gene also reduced tumorigenicity and cell migration in many cancer-derived cell lines (Ref. 24 and references therein).
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Drs. N. Dusetti, J. M. Frigerio, and S. Kaplanski for help and suggestions. The Hoxa-7 LacZ and TK LacZr constructs were a generous gift from Dr. P. Gruss and B. Meyer (Max Planck Institute for Biophysical Chemistry, Göttingen, Germany).
![]() |
FOOTNOTES |
---|
* This work was supported by grants from the Ligue Nationale contre le Cancer (Comité des Bouches du Rhône), the Association pour la Recherche sur le Cancer, and the Fédération Nationale des Centres de Lutte contre le Cancer.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These authors contributed equally to this work.
¶ Fellow of the Fondation pour la Recherche Médicale.
To whom correspondence should be addressed: U.315 INSERM, 46 Bd
de la Gaye, F-13009 Marseille, France. Tel.: 33-491-172176; Fax:
33-491-266219; E-mail: iovanna{at}marseille.inserm.fr.
1 The abbreviations used are: MTT, 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; PMA, phorbol 12-myristate 13-acetate.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|